Scientific Presentations & Publications

Title Published Date
RARA Pathway Activation Biomarkers in Study SY-1425-201 Define a New Subset of AML and MDS Patients and Correlate with Myeloid Differentiation Following Ex Vivo SY 1425 Treatment Jul 01 2020
Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients Jul 01 2020
SY-1425, A Potent and Selective RARA Agonist, Reprograms AML Cells for Differentiation Along Distinct Lineages Uncovering PD Markers for Clinical Studies Jul 01 2020
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options Jul 01 2020
A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents Jul 01 2020
Ex Vivo Drug Sensitivity Profiling In Myelodysplastic Syndrome (MDS) Patients Defines Novel Drug Sensitivity Patterns For Predicting Clinical Therapeutic Outcomes Jul 01 2020
Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy Jul 01 2020
Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling Jul 01 2020
Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression Jul 01 2020
Differential drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling Apr 11 2018
Ex Vivo Drug Response Profiling Defines Novel Drug Sensitivity Patterns for Predicting Clincal Therapeutic Responses in Myeloid Neoplasms Mar 11 2018

Page 2 of 2

To learn more, share ideas, or join our mission.
Contact us today!

CONNECT WITH US

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.